ClinicalTrials.gg
CompletedNCT06149247Updated Aug 20, 2025Results posted

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

A Phase 2 interventional study of Hypericin and Mechlorethamine Topical Gel in Cutaneous T-Cell Lymphoma/Mycosis Fungoides, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by Soligenix · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Enrollment
218th of 279
10 · median 32
Started
2023
with 6 others
Phase 2
101 of 360
8 open now
Registered
347th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 218th largest by enrollment of the 279 interventional ones that give a count, is one of 7 that started in 2023, is one of 101 in phase 2, and was the 347th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.

Read the detailed description

Participants will be randomized to receive HyBryte or Valchlor in a 1:1 randomization. Participants will be treated for 12 weeks and follow-up visits will be conducted 1, 2, and 4 weeks after completion of the treatment phase of the trial.

Prior to randomization, each participant will have at least 3 and up to 5 lesions identified (index lesions) that will be evaluated during the treatment phase and during the follow-up visits.

03

Conditions studied

  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Browse trials for

Keywords

  • CTCL
  • MF
  • Hypericin
  • HyBryte
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 3 active treatment-accessible CTCL lesions
  • Subjects must have a clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosis fungoides), Stage IA, IB, or Stage IIA
  • Subjects willing to follow the clinical protocol and voluntarily give their written
  • Female subjects not pregnant nor nursing and willing to undergo a pregnancy test within 30 days prior to treatment initiation

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction to any of the components of HyBryte or mechlorethamine (Valchlor)
  • Pregnancy or mothers who are breast-feeding
  • All women of (WOCBP) and males with female partners who are WOCBP not willing to use effective
  • Subjects with history of sun or photosensitive dermatoses (eg, porphyria, systemic lupus erythematosus (SLE), Sjogren's syndrome, etc.)
  • Subjects whose condition is spontaneously improving
  • Subjects receiving Valchlor (or any topical compound containing Mechlorethamine) in the preceding 2 months
  • Subjects receiving topical or other topical treatments (eg, targretin gel) on treatment accessible lesions for CTCL within 2 weeks of enrollment
  • Subjects receiving systemic steroids, psoralen ultraviolet A (UVA) radiation therapy (PUVA), narrow band ultraviolet B (UVB) light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment
  • Subjects who have received electron beam irradiation within 3 months of enrollment
  • Subjects with a history of significant systemic
  • Subjects taking other drugs or drugs of abuse within 30 days of enrollment
  • Subject has any condition that, in the judgment of the Investigator, is likely to interfere with participation in the study
  • Subjects receiving drugs known to cause photosensitization within 2 weeks of starting HyBryte therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    HyBryte (0.25 % hypericin)

    HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 6 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 12 weeks.

    Drug: Hypericin

  • Active comparator
    Valchlor (mechlorethamine)

    Valchlor (0.016% mechlorethamine) gel will be applied to CTCL lesions once daily for 12 weeks.

    Drug: Mechlorethamine Topical Gel

Interventions

  • HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

    Also known as: HyBryte, SGX301

  • DrugMechlorethamine Topical Gel

    Drug page: MechlorethamineStudies of MechlorethamineMechlorethamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Valchlor is an FDA-approved drug for the treatment of CTCL.

    Also known as: Valchlor

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score

    A treatment response is defined as a ≥50% improvement in mCAILS score at Week 12 when compared to the mCAILS score at baseline. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

    Time frame: 12 weeks

07

Results

Posted Aug 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneHyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)
Started55
Completed54
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryNumber of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score

A treatment response is defined as a ≥50% improvement in mCAILS score at Week 12 when compared to the mCAILS score at baseline. The Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score
ParticipantsHyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)
Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score31

Adverse events

Collected over From enrollment until end of follow-up, up to 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HyBryte (0.25 % Hypericin)0/5 (0%)0/5 (0%)2/5 (40%)
Valchlor (Mechlorethamine)0/5 (0%)0/5 (0%)3/5 (60%)
Most frequent other events
Most frequent other events
EventHyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)
Swollen lymph nodesBlood and lymphatic system disorders1/50/5
Allergic contact dermatitisGeneral disorders0/51/5
DermatitisGeneral disorders0/51/5
RashGeneral disorders0/51/5
SensitivityGeneral disorders0/51/5
COVID-19 infectionInfections and infestations1/50/5
Neck pain/inflammationMusculoskeletal and connective tissue disorders1/50/5
Id reactionSkin and subcutaneous tissue disorders0/51/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)HyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)Total
Mean56.2 ± 19.1862.4 ± 13.4859.3 ± 16.86
Sex: Female, Male
Sex: Female, Male(Participants)HyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)Total
Female235
Male325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White459
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HyBryte (0.25 % Hypericin)Valchlor (Mechlorethamine)Total
Hispanic or Latino000
Not Hispanic or Latino5510
Unknown or Not Reported000
08

Study locations

1 site
  • Rochester Skin Lymphoma Medical Group
    Fairport, New York 14450, United States
09

References and documents

Publications

  • Poligone B, Pullion C, Rumage A, Straube R, Donini O, Schaber CJ, Gilmore ES. Results from a Pilot Study of HyBryte (Topical Synthetic Hypericin) Versus Valchlor(R) (Mechlorethamine) in the Treatment of CTCL. Oncol Ther. 2026 Jun;14(2):693-705. doi: 10.1007/s40487-026-00430-1. Epub 2026 Apr 1. PubMed 41920467 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in May 2024, 5 months.

Results were first posted in Aug 2025, 1 year 2 months after primary completion.

Of 42 phase 2 interventional studies under Mycosis Fungoides, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 111. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 28, 2023
StartActual
Dec 5, 2023
Primary completionActual
May 31, 2024
CompletionActual
Jun 27, 2024
Results first posted
Aug 20, 2025
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06149247
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Nov 28, 2023
Start date
Dec 5, 2023
Primary completion
May 31, 2024
Completion
Jun 27, 2024
Results posted
Aug 20, 2025
Last update
Aug 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hypericin

Start the discussion